{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:46Z","timestamp":1740106906231,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T00:00:00Z","timestamp":1714262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00277-024-05769-x","type":"journal-article","created":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T11:01:16Z","timestamp":1714302076000},"page":"2533-2539","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tixagevimab\/cilgavimab (AZD7442\/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy"],"prefix":"10.1007","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9106-9326","authenticated-orcid":false,"given":"Yoo Jin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Ki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Hyuk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiwon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-suk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Cheol","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,28]]},"reference":[{"key":"5769_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/s41375-022-01578-1","volume":"36","author":"S Cesaro","year":"2022","unstructured":"Cesaro S, Ljungman P, Mikulska M et al (2022) Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia 36:1467\u20131480. https:\/\/doi.org\/10.1038\/s41375-022-01578-1","journal-title":"Leukemia"},{"key":"5769_CR2","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas EJ, Angulo FJ, McLaughlin JM et al (2021) Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 397:1819\u20131829. https:\/\/doi.org\/10.1016\/S0140-6736(21)00947-8","journal-title":"Lancet"},{"key":"5769_CR3","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41375-021-01302-5","volume":"35","author":"P Ljungman","year":"2021","unstructured":"Ljungman P, de la Camara R, Mikulska M et al (2021) COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia 35:2885\u20132894. https:\/\/doi.org\/10.1038\/s41375-021-01302-5","journal-title":"Leukemia"},{"key":"5769_CR4","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1182\/blood.2020008824","volume":"136","author":"A Vijenthira","year":"2020","unstructured":"Vijenthira A, Gong IY, Fox TA et al (2020) Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136:2881\u20132892. https:\/\/doi.org\/10.1182\/blood.2020008824","journal-title":"Blood"},{"key":"5769_CR5","doi-asserted-by":"publisher","first-page":"e2331617","DOI":"10.1001\/jamanetworkopen.2023.31617","volume":"6","author":"SM Hosseini-Moghaddam","year":"2023","unstructured":"Hosseini-Moghaddam SM, Shepherd FA, Swayze S, Kwong JC, Chan KKW (2023) SARS-CoV-2 Infection, hospitalization, and mortality in adults with and without cancer. JAMA Netw Open 6:e2331617. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.31617","journal-title":"JAMA Netw Open"},{"key":"5769_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.cmi.2018.04.024","volume":"25","author":"E Pelfrene","year":"2019","unstructured":"Pelfrene E, Mura M, Cavaleiro Sanches A, Cavaleri M (2019) Monoclonal antibodies as anti-infective products: a promising future? Clin Microbiol Infect 25:60\u201364. https:\/\/doi.org\/10.1016\/j.cmi.2018.04.024","journal-title":"Clin Microbiol Infect"},{"key":"5769_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL (2021) Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol 21:382\u2013393. https:\/\/doi.org\/10.1038\/s41577-021-00542-x","journal-title":"Nat Rev Immunol"},{"key":"5769_CR8","doi-asserted-by":"publisher","first-page":"eabl8124","DOI":"10.1126\/scitranslmed.abl8124","volume":"14","author":"YM Loo","year":"2022","unstructured":"Loo YM, McTamney PM, Arends RH et al (2022) The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Transl Med 14:eabl8124. https:\/\/doi.org\/10.1126\/scitranslmed.abl8124","journal-title":"Sci Transl Med"},{"key":"5769_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost SJ, Gilchuk P, Case JB et al (2020) Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584:443\u2013449. https:\/\/doi.org\/10.1038\/s41586-020-2548-6","journal-title":"Nature"},{"key":"5769_CR10","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","volume":"26","author":"SJ Zost","year":"2020","unstructured":"Zost SJ, Gilchuk P, Chen RE et al (2020) Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med 26:1422\u20131427. https:\/\/doi.org\/10.1038\/s41591-020-0998-x","journal-title":"Nat Med"},{"key":"5769_CR11","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S et al (2022) Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med 386:2188\u20132200. https:\/\/doi.org\/10.1056\/NEJMoa2116620","journal-title":"N Engl J Med"},{"key":"5769_CR12","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1182\/blood.2021014124","volume":"139","author":"L Pagano","year":"2022","unstructured":"Pagano L, Salmanton-Garcia J, Marchesi F et al (2022) COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood 139:1588\u20131592. https:\/\/doi.org\/10.1182\/blood.2021014124","journal-title":"Blood"},{"key":"5769_CR13","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-023-01423-7","volume":"16","author":"F Marchesi","year":"2023","unstructured":"Marchesi F, Salmanton-Garcia J, Buquicchio C et al (2023) Passive pre-exposure immunization by tixagevimab\/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry. J Hematol Oncol 16:32. https:\/\/doi.org\/10.1186\/s13045-023-01423-7","journal-title":"J Hematol Oncol"},{"key":"5769_CR14","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/blood.2022017257","volume":"140","author":"L Pagano","year":"2022","unstructured":"Pagano L, Salmanton-Garcia J, Marchesi F et al (2022) Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood 140:2773\u20132787. https:\/\/doi.org\/10.1182\/blood.2022017257","journal-title":"Blood"},{"key":"5769_CR15","doi-asserted-by":"publisher","first-page":"e0098921","DOI":"10.1128\/jcm.00989-21","volume":"59","author":"BT Bradley","year":"2021","unstructured":"Bradley BT, Bryan A, Fink SL et al (2021) Anti-SARS-CoV-2 antibody levels measured by the advisedx SARS-CoV-2 assay are concordant with previously available serologic assays but are not fully predictive of sterilizing immunity. J Clin Microbiol 59:e0098921. https:\/\/doi.org\/10.1128\/jcm.00989-21","journal-title":"J Clin Microbiol"},{"key":"5769_CR16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.tim.2020.11.002","volume":"29","author":"R West","year":"2021","unstructured":"West R, Kobokovich A, Connell N, Gronvall GK (2021) COVID-19 antibody tests: a valuable public health tool with limited relevance to individuals. Trends Microbiol 29:214\u2013223. https:\/\/doi.org\/10.1016\/j.tim.2020.11.002","journal-title":"Trends Microbiol"},{"key":"5769_CR17","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","volume":"40","author":"R Stuver","year":"2022","unstructured":"Stuver R, Shah GL, Korde NS et al (2022) Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell 40:590\u2013591. https:\/\/doi.org\/10.1016\/j.ccell.2022.05.007","journal-title":"Cancer Cell"},{"key":"5769_CR18","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1038\/s41467-022-31615-7","volume":"13","author":"JB Case","year":"2022","unstructured":"Case JB, Mackin S, Errico JM et al (2022) Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun 13:3824. https:\/\/doi.org\/10.1038\/s41467-022-31615-7","journal-title":"Nat Commun"},{"key":"5769_CR19","doi-asserted-by":"publisher","first-page":"103905","DOI":"10.1016\/j.msard.2022.103905","volume":"63","author":"WL Conte","year":"2022","unstructured":"Conte WL, Golzarri-Arroyo L (2022) Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters. Mult Scler Relat Disord 63:103905. https:\/\/doi.org\/10.1016\/j.msard.2022.103905","journal-title":"Mult Scler Relat Disord"},{"key":"5769_CR20","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ekir.2022.08.019","volume":"7","author":"F Aqeel","year":"2022","unstructured":"Aqeel F, Geetha D (2022) Tixagevimab and Cilgavimab (Evusheld) in rituximab-treated antineutrophil cytoplasmic antibody vasculitis patients. Kidney Int Rep 7:2537\u20132538. https:\/\/doi.org\/10.1016\/j.ekir.2022.08.019","journal-title":"Kidney Int Rep"},{"key":"5769_CR21","doi-asserted-by":"publisher","first-page":"113243","DOI":"10.1016\/j.jim.2022.113243","volume":"503","author":"GN Maine","year":"2022","unstructured":"Maine GN, Krishnan SM, Walewski K, Trueman J, Sykes E, Sun Q (2022) Clinical and analytical evaluation of the Abbott AdviseDx quantitative SARS-CoV-2 IgG assay and comparison with two other serological tests. J Immunol Methods 503:113243. https:\/\/doi.org\/10.1016\/j.jim.2022.113243","journal-title":"J Immunol Methods"},{"key":"5769_CR22","doi-asserted-by":"publisher","first-page":"e0028821","DOI":"10.1128\/jcm.00288-21","volume":"59","author":"E English","year":"2021","unstructured":"English E, Cook LE, Piec I, Dervisevic S, Fraser WD, John WG (2021) Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012\/V1 (United Kingdom) and VOC 202012\/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods. J Clin Microbiol 59:e0028821. https:\/\/doi.org\/10.1128\/jcm.00288-21","journal-title":"J Clin Microbiol"},{"key":"5769_CR23","doi-asserted-by":"publisher","first-page":"7575","DOI":"10.3390\/jcm12247575","volume":"12","author":"S Mink","year":"2023","unstructured":"Mink S, Fraunberger P (2023) Anti-SARS-CoV-2 Antibody Testing: Role and Indications. J Clin Med 12:7575. https:\/\/doi.org\/10.3390\/jcm12247575","journal-title":"J Clin Med"},{"key":"5769_CR24","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s10096-021-04169-7","volume":"40","author":"L M\u00fcller","year":"2021","unstructured":"M\u00fcller L, Ostermann PN, Walker A et al (2021) Sensitivity of anti-SARS-CoV-2 serological assays in a high-prevalence setting. Eur J Clin Microbiol Infect Dis 40:1063\u20131071. https:\/\/doi.org\/10.1007\/s10096-021-04169-7","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5769_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/infdis\/jiaa273","volume":"222","author":"PD Burbelo","year":"2020","unstructured":"Burbelo PD, Riedo FX, Morishima C et al (2020) Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis 222:206\u2013213. https:\/\/doi.org\/10.1093\/infdis\/jiaa273","journal-title":"J Infect Dis"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05769-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05769-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T16:05:32Z","timestamp":1720109132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05769-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,28]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["5769"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05769-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2024,4,28]]},"assertion":[{"value":"29 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by the institutional review boards and ethics committees of each participating institution (UUH-IRB-2022\u201307-029). The trial was registered on the Clinical Research Information System website (trial number KCT0007617).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No potential conflicts of interest relevant to this article were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}